Companies interested in exclusively licensing technology that prevents and treats diabetic retinopathy can now forward their proposals to the Inova Unicamp Innovation Agency. The notice, which had an extended deadline, receives proposals until August 18th, at 17:30 pm, aims to make public the contracting of the most advantageous proposal for the exclusive use and commercialization of the technology entitled “Pharmaceutical Composition and Formulation for Non-Invasive Ocular Treatment and its uses.”
Developed by researchers from the Faculty of Medical Sciences (FCM) at Unicamp, the technology appears as a non-invasive alternative for the treatment of the disease, caused by neural and vascular changes in the retina, generated by the toxic effect of high blood glucose levels (glucose in the serum). Diabetic Retinopathy (DR), in more advanced stages, can lead to vision loss. Currently, the options available for treatment include laser photocoagulation, intravitreal injections or even surgery, causing discomfort and inconvenience to the patient.
More about the research and the notice on the Inova page
